Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Torres-Esquius S"'
Autor:
Torres-Esquius S; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Beas F; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Chen-Liang TH; Department of Hematology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Murcia, Spain., Pomares H; Department of Hematology, Institut Català d'Oncologia. Hospital Duran i Reynals, IDIBELL. Hospitalet, Badalona, Barcelona, Spain., Santiago M; Department of Hematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain., Varela ND; Department of Hematology, Hospital Universitario Central de Asturias, Instituto. Universitario (IUOPA), Instituto de Investigación del Principado de Asturias (ISPA), Oviedo, Spain., Liquori A; Department of Hematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain., Hernandez F; Department of Hematology, Hospital Virgen de las Nieves, Granada, Spain., Xicoy B; Department of Hematology, Hospital Germans Trias i Pujol, Badalona, Spain., Hermosín L; Department of Hematology, Hospital de Jerez, Cádiz, Spain., Arnan M; Department of Hematology, Institut Català d'Oncologia. Hospital Duran i Reynals, IDIBELL. Hospitalet, Badalona, Barcelona, Spain., Tazón-Vega B; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Blanco A; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Cervera J; Department of Hematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain., Diez-Campelo M; Department of Hematology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain., Lozano ML; Department of Hematology, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Murcia, Spain., Valcárcel D; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Bosch F; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Montoro MJ; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Jerez A; Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Publikováno v:
British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 503-509. Date of Electronic Publication: 2024 Apr 19.
Autor:
Pla-Juher H; Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Avinguda de França s/n, 17707, Girona, Spain. hpla@iconcologia.net.; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. hpla@iconcologia.net.; Department of Epidemiology and Cancer Register, Girona, Spain. hpla@iconcologia.net., Pardo M; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain., Izquierdo ÀJ; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain.; Department of Epidemiology and Cancer Register, Girona, Spain., Darder E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain.; Department of Epidemiology and Cancer Register, Girona, Spain., Carbó A; Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Avinguda de França s/n, 17707, Girona, Spain.; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.; Department of Epidemiology and Cancer Register, Girona, Spain., Munté E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain., Torres-Esquius S; Department of Medical Oncology, Vall d'Hebrón Hospital, Barcelona, Spain., Balmaña J; Department of Medical Oncology, Vall d'Hebrón Hospital, Barcelona, Spain., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, Madrid, Spain., Brunet JM; Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Avinguda de França s/n, 17707, Girona, Spain.; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain.; Department of Epidemiology and Cancer Register, Girona, Spain., Barretina-Ginesta MP; Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Avinguda de França s/n, 17707, Girona, Spain.; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.; Department of Epidemiology and Cancer Register, Girona, Spain.
Publikováno v:
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Apr; Vol. 26 (4), pp. 1033-1037. Date of Electronic Publication: 2023 Sep 08.
Autor:
Torres-Esquius S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Translational Medicine, DNA Damage Response Department, AstraZeneca, Barcelona, Spain., Gutiérrez-Enríquez S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Romey M; Institute of Pathology, Universitätsklinikum Marburg, Marburg, Germany., Teulé À; Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Llort G; Department of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain., Herrero A; Department of Medical Oncology, Hospital Miguel Servet de Zaragoza, Zaragoza, Spain., Sánchez-Henarejos P; Department of Medical Oncology, Clinical University Hospital Virgen Arrixaca, Murcia, Spain., Vallmajó A; Genetic Counseling Unit, Arnau de Vilanova University Hospital, Lleida, Spain., González-Santiago S; Department of Medical Oncology, Hospital San Pedro de Alcántara, Cáceres, Spain., Chirivella I; Cancer Genetic Counseling, Hospital Clínico Universitario de Valencia, Valencia, Spain., Cano JM; Department of Medical Oncology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Graña B; Department of Medical Oncology, Xerencia de Xestión Integrada de A Coruña, Coruña, Spain., Simonetti S; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Díaz de Corcuera I; Department of Medical Oncology, Hospital Universitario de Galdakao, Galdakao-Usansolo, Spain., Ramon Y Cajal T; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Sanz J; Unidad de Cáncer Familiar y Hereditario, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain., Serrano S; Department of Medical Oncology, Institute of Oncology of Southern Catalonia (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain., Otero A; Institute of Oncology and Molecular Medicine of Asturias (IMOMA) S. A., Oviedo, Spain., Churruca C; Department of Medical Oncology, Hospital Universitario Donostia, San Sebastián, Gipuzkoa, Spain., Sánchez-Heras AB; Cancer Genetic Counselling Unit, Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain., Servitja S; Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain., Guillén-Ponce C; Department of Medical Oncology, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, Girona, Spain.; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain., Denkert C; Institute of Pathology, Universitätsklinikum Marburg, Marburg, Germany., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Publikováno v:
JAMA network open [JAMA Netw Open] 2024 Apr 01; Vol. 7 (4), pp. e247811. Date of Electronic Publication: 2024 Apr 01.
Autor:
Rezqallah A; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Torres-Esquius S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cruellas M; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Martinez MT; Medical Oncology Department, INCLIVA Biomedical Research Institute, Hospital Clínico de València, University of Valencia, Valencia, Spain., Romey M; Institute of Pathology, Universitätsklinikum Marburg, Marburg, Germany., Denkert C; Institute of Pathology, Universitätsklinikum Marburg, Marburg, Germany., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Chirivella I; Medical Oncology Department, INCLIVA Biomedical Research Institute, Hospital Clínico de València, University of Valencia, Valencia, Spain., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2024 Mar; Vol. 8, pp. e2300446.
Autor:
López-Fernández A; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Genetic and Microbiology Department, Universitat Autònoma de Barcelona, Barcelona, Spain., Villacampa G; Oncology Data Science (ODysSey) Group, VHIO, Barcelona, Spain., Salinas M; Hereditary Cancer Program, Duran i Reynals Hospital, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Grau E; Genetic and Microbiology Department, Universitat Autònoma de Barcelona, Barcelona, Spain.; Hereditary Cancer Program, Duran i Reynals Hospital, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Darder E; Hereditary Cancer Program, Josep Trueta University Hospital, Catalan Institute of Oncology, IDIBGI, Girona, Spain., Carrasco E; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Solanes A; Hereditary Cancer Program, Germans Trias i Pujol Hospital, Catalan Institute of Oncology, Barcelona, Spain., Velasco A; Hereditary Cancer Program, Josep Trueta University Hospital, Catalan Institute of Oncology, IDIBGI, Girona, Spain., Torres M; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Munté E; Hereditary Cancer Program, Duran i Reynals Hospital, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Iglesias S; Hereditary Cancer Program, Duran i Reynals Hospital, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Torres-Esquius S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Tuset N; Genetic Counseling Unit, Arnau de Vilanova University Hospital, Lleida, Spain., Diez O; Hereditary Cancer Genetics Group, Area of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Lázaro C; Hereditary Cancer Program, Molecular Diagnosis Laboratory, Catalan Institute of Oncology, Barcelona, Spain., Brunet J; Hereditary Cancer Program, Duran i Reynals Hospital, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.; Medical Sciences Dpt. School of Medicine, University of Girona, Girona, Spain., Corbella S; School of Psychology, Education and Sports Sciences, Ramon Llull University - Blanquerna, Barcelona, Spain., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Publikováno v:
Journal of genetic counseling [J Genet Couns] 2023 Aug; Vol. 32 (4), pp. 778-787. Date of Electronic Publication: 2023 Feb 07.
Autor:
González, A. Pérez, Peralta-Garzón, S., Palomo, L., Navarro, V., Yordi, A. Molero, Tazón-Vega, B., Calvete, O., Salamero, O., Saumell, S., Rivero, E., Zamora, E., Saoudi, N., Fariñas, L., Torres-Esquius, S., Novoa, S., Garrido, S., Sola, M., Campelo, M., Alfonso, A., Montoro, M.J., Valcárcel, D.
Publikováno v:
In Leukemia Research May 2023 128 Supplement
Autor:
Novoa, S., Torres-Esquius, S., Tazón-Vega, B., Blanco, A., Saumell, S., González, A. Pérez, Yordi, A. Molero, Garrido, S., Bosch, M., Valcárcel, D., Jerez, A., Montoro, M.J.
Publikováno v:
In Leukemia Research May 2023 128 Supplement
Autor:
Montoro, M.J., Torres-Esquius, S., Verdejo-Sánchez, M., Carrillo-Tornel, S., Chen-Liang, T.H., Hernández-Mohedo, F., Martínez-Francés, A., Campelo, M., Valcárcel, D., Jerez, A.
Publikováno v:
In Leukemia Research May 2023 128 Supplement
Autor:
Llop-Guevara A, Torres-Esquius S, Romey M, Gutierrez-Enriquez S, Nuciforo P, Diez O, Pursals G, Teule A, Vallmajo A, De Corcuera I, Gonzalez I, Santiago S, Henarejos P, Buxo J, Ponce C, Sanchez A, Vidal J, Denkert C, Elizalde V, Balmana J
Publikováno v:
ANNALS OF ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b14db5bcb3df871ab10fbce677c52985
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13653
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13653
Autor:
Carrasco E; Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Department of Pediatrics, Obstetrics and Gynecology, Preventative Medicine and Public Health, Autonomous University of Barcelona, Barcelona, Spain.; Hereditary Cancer Genetics Group, Medical oncology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., López-Fernández A; Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Hereditary Cancer Genetics Group, Medical oncology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., Codina-Sola M; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Valenzuela I; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Cueto-González AM; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Villacampa G; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., Navarro V; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., Torres-Esquius S; Hereditary Cancer Genetics Group, Medical oncology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., Palau D; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Cruellas M; Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Hereditary Cancer Genetics Group, Medical oncology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., Torres M; Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain., Perez-Dueñas B; Paediatric Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Universitat Autónoma de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain., Abulí A; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Diez O; Hereditary Cancer Genetics Group, Medical oncology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Sábado-Álvarez C; Department of Pediatric Oncology and Hematology, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain., García-Arumí E; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.; Research Group on Neuromuscular and Mitochondrial Disorders, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain., Tizzano EF; Department of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516], ERN-ITHACA, Barcelona, Spain., Moreno L; Department of Pediatric Oncology and Hematology, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain lucas.moreno@vallhebron.cat.; Childhood Cancer and Blood Disorders Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Balmaña J; Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Hereditary Cancer Genetics Group, Medical oncology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain.; Member of the European Reference Network on GENTURIS, ID: HP-ERN-2016 739547, GENTURIS, Barcelona, Spain.
Publikováno v:
Journal of medical genetics [J Med Genet] 2023 Jul; Vol. 60 (7), pp. 685-691. Date of Electronic Publication: 2022 Nov 29.